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Summary: A kinetic enzymolqgical assay for methotrexate in serum is described; the results are available after 1.5
hours. The lower limit of sensivity is 50 nmol/1; the day-to-day variation coefficients compare favourably with other
procedures (about 1% in the 200-600 nmol/1 range). The method uses purified dihydrofolic acid reductase from
bovine liver. The problem of its instability in the assay is circumvented by several measures, e.g. the use of a reaction
rate analyser.
Schnelle enzymatische Bestimmung von Methotrexat im Serum
Zusammenfassung: Es wird eine kinetische Bestimmung von Methotrexat im Serum beschrieben, deren Ergebnisse in
1,5 Stunden erzielt werden können. Bei dem Verfahren wurde das Hilfenzym Dihydrofolatreduktase benutzt, das in
der Gebrauchskonzentration einigermaßen instabil ist. Dieser Nachteil, wie auch die Instabilität anderer benötigter
Reagenzien wurden durch verschiedene Maßnamen, z.B. durch die Anwendung eines automatischen Analysengerätes,
beseitigt, Die Empfindlichkeitsgrenze beträgt 50 nmol/1, der Variationskoeffizient im klinisch signifikanten Bereich
von 200^600 nmol/1 ist ungefähr 7%.
Introduction
Methotrexate, an inhibitor of dihydrofolate reductase
(EC 1.5.1.3), plays an important role in the treatment of
several neoplastic diseases (1). In recent years large doses
of methotrexate have been increasingly used. A serious
problem is its toxicity, which can lead to life-threatening
situations. The toxic effect of methotrexate is related to
the rate of its disappearance in blood. The serum levels
at about 48 hours and 72 hours after the start of admini-
stration of methotrexate are especially critical for the
prediction of toxicity, and for the design of appropriate
measures against it. Rapid quantitation of serum metho-
trexate, i.e. within a few hours of taking a blood sample
is therefore necessary during therapy.
Competitive protein binding methods (2-4) use short
incubation periods (in the order of minutes) but involve
laborious subsequent manipulations. Radioiimmunological
methods require long incubation periods (6—36 hours)
(5-8), and the results are therefore generally not available
the same day.
The competitive protein binding and radioimmunological
methods measure over a narrow range, in the order of a
few tenths and a few hundred nmol/1, respectively, the
methotrexate concentrations, however, msy vary from
zero to levels of a few mmol/1. It is therefore pure
chance whether or not the chosen serum dilution for
the first measurement is appropriate for the methotrexate
concentration of the sample. Practice has shown that in
some cases the measurements have to be repeated, not once
but sometimes several times, to obtain measurable con-
centrations. This implies a clinically unacceptable long
interval until the methotrexate concentration is known,
if the above methods are used.
These disadvantages are less marked in enzyme inhib-
ition assays (9-12), which yield results more quickly.
The enzyme inhibition assay has been available for over
ten years (9-12), but descriptions are either not suffi-
ciently detailed or do not fully take into account the
various factors, e.g. instability of the reagents, period of
validity of the calibration curve, effect of proteins,
etc. We found that these factors have to be evaluated
more fully before reproducible results can be obtained,
and we adapted the enzymological method originally
described byBertino & Fisher (12) to produce a
reliable assay. In addition, the method presented here
makes it possible to.assay various samples for metho-
trexate within 90 minutes, once the working solutions
are ready for use, even if the above-mentioned repeated
runs with different dilutions are required.
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Dissolve 6.5 g Na2HP04 · 12H20 and 1.3 g NaH2PO4 · H2O
(0.055 mol/l) in 500 ml twice distilled water. Adjust pH to 6.50.
Dihydrofolic acid reductase
Stock solution
Dihydrofolic acid reductase from bovine liver was purchased
from Sigma Chemical Co., St. Louis, USA. It was obtained as
a suspension of 1 or 5 Units in 0.230 or 0.150 ml respectively
of ammonium sulphate solution (3.6 mol/l). An aliquot of
phosphate buffer is added to dihydrofolic acid reductase to
prepare a solution of 2000 U/l. This is stable for 2 weeks at
4°C.
Working reagent
The stock solution is diluted twenty times with cold (4°C)
phosphate buffer. The working reagent is unstable and should
be used immediately after its preparation.
Dihydrofolic acid solution
Dihydrofolic acid was purchased from Sigma Chemical Co.,
St. Louis, USA, in sealed ampoules. Dihydrofolic acid (18 mg)
and N-acetyl cysteine (90 mg) are suspended in 30 ml cold
(4°C) HC1 (0.005 mol/l). A fine suspension is obtained with
the aid of a glass rod. While stirring, the suspension is trans-
ferred in 2.5 ml aliquots to glass tubes. Stored, capped and
frozen, this reagent is stable for two months.
The working reagent is prepared by thawing one aliquot,
adding an equal volume of cold glycerol, and mixing.
Methotrexate standard solution (600 nmol/1)
Methotrexate was produced by Lederle and designated as 94%
pure. An aliquot (4.0 mg) of methotrexate is dissolved in
about 20 ml twice distilled water. A minimal quantity of 1 mol/l
NaOH is added to promote dissolution. The volume is made up
to 50.0 ml. The solution is diluted ten times with physiological
saline to obtain 0.0176 mmol/1. One ml of the latter pre-
paration is thoroughly mixed with normal serum to give a final
concentration of 600 nmol/1. The standard in normal serum is
stored in 1.1 ml aliquots which are kept frozen at -20°C.
Caution: Another commercial methotrexate batch was found
to contain only 60% methotrexate "activity", resulting in a
methotrexate concentration falsely increased by a factor of
approx. 1.66.
NADPH solution (0.002 mol/l)
This solution is prepared by dissolving an aliquot (17 mg) of
reduced nicotinamide-adenine dinucleotide phosphate (NADPH)-
tetrasodium salt (Boehringer Mannheim, enzymatic analysis
69%, Grade II) in 10 ml NaHC03 solution (0.01 mol/l). This
preparation is kept at room temperature and the unused portion
is discarded at the end of the day.
Incubation buffer
The incubation buffer is prepared by mixing eight volumes of
H20, one volume of KC1 solution (1.5 mol/l) and one volume of
sodium citrate solution (1.0 mol/l) and then adding 300 mg N-
acetyl cysteine (18.4 mmol/1) per 100 ml of the above mixture.
The pH should be carefully adjusted to 5.9. The incubation
buffer can be kept 3 weeks at 4°C.
NADPH buffer mixture
NADPH solution (0.1 ml) is added to 7.0 ml incubation buffer.
It should be prepared fresh before use.
Instrumentation
Settings ofLKB reaction rate analyser
Filter: 343, reaction course: decrease, backoff (A)0, range:
0-0.2, measuring time 1.0 minute, chart speed 60 mm/min,
temperature 30°C.




NADPH buffer 10 μΐ
mixture


















Ο μ Ι ο Γ ί Ο μ Ι ο Γ ~
20 μΐ or 30 μΐ
40 μΐ or 30 μΐ or -
20 μ! or 10 μΐ
40 μΐ







*) Activity at zero-concentration of methotrexate
2) Total volume of normal serum and standard in normal serum
is 40 μΐ.
3) Cerebrospinal fluid (CSF) can be measured by following the
procedure for control, with the exception that 10 μΐ CSF is
added after addition of the NADPH buffer mixture. Then,
normal serum etc. is added. To the standards, 10 μΐ water is
added to keep total volumes identical. After reading the
standard curve results are multiplied by 4.0.
4) Starting reagent.
Assay procedure
The methodology is described in table 1. Immediately after
adding the reagents the cuvettes should be placed in the racks
and measurement should be started. The measurement is done
with repeating units of two racks. We advise the following '
order: first rack: cuvettes containing "activity at zero concen-
tration" of methotrexate, and standards 600,450, 300 and
150 (nmol/1), sample 1-5 (including control). Second rack:
cuvettes with the duplicates of the cuvettes in the first. The
third and the fourth racks should again contain standards and
samples 6-10 in the sequence as described for the first and
second racks. Serum samples containing methotrexate in con-
centrations exeeding 600 nmol/1 are diluted with the same
normal serum as that used for the construction of the standard
curve. If after completion of measurements some samples are
to be assayed again (e.g. in diluted form), the whole procedure
(standards, etc.) is repeated and freshly prepared dihydrofolic
acid reductase working reagent should be used. Figure 1 shows
a typical standard curve.
Results and Discussion
Storage of dihydrofolic acid in hydrochloric acidj in the
presence of a thiol to minimize air oxidation, is based on
work published by Futterman (13) and has also been
described by Folk et aL (10).
Using the solution of NADPH with bicarbonate, repro-
ducible results were obtained with either fresh NADPH
solutions or those prepared 6 hours before. It should be
noted that,'at the final NADPH concentratipn, about
70% of the optimal dihydrofolic acid reductase activity
is obtained. Increasing the NADPH concentration did not
seem attractive since dihydrofolic acid itself contributes
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Fig. 1. The decrease of absoibance plotted against the metho-
trexate concentration. The standards were run in
duplicate. The lowest concentration which could be
measured was 50 nmol/1.
considerably to the overall absorbance (13). We checked
the occurrence of side reactions which could interfere
with the assay. For this purpose we measured metho-
trexate in various sera with an increased serum 5'-nucleo-
tidase,. which is an indication of liver disorders. The di-
hydrofolic acid was replaced by phosphate buffer
containing ammonium sulphate in the same concentration
as used in the dihydrofolic acid working solution. No
change in absorbance could be registered. Identical ob-
servations were made when the enzyme working solution
was replaced by buffer, the other reagents remaining
unchanged.
Methotrexate is unstable in aqueous solution. After
thawing of a frozen aqueous solution, persistent preci-
pitates may form. For this reason a solution of metho-
trexate in normal serum was preferred as standard.
Another reason for using methotrexate in normal serum
as a standard is that, with an aqueous standard, higher
activities have occasionally been measured in the ab-
sence than in the presence of serum. Surprisingly this
effect was not always reproducible. It is our experience
that, stored frozen, the standard in normal serum is
stable for at least two months. During development of
the method it was observed that the sequence of
addition of reagents influences the slope and reprodu-
cibility of the standard curve. Preincubation with a
very small quantity of NADPH, as recommended by
Arons et al. (2), and the sequence of reagents as
described in table 1, resulted in the steepest standard
curve we could obtain. Unfortunately the reproducibility
of the standard curve was less when the performance of
the duplicates was delayed by placing the cuvettes of
the duplicates in, say, the fifth rack, the reproducibility
was even less when the recommended sequence of adding
reagents was changed. Obviously some factor that we
cannot explain shifts the standard curve in the course of
time. This phenomenon may be illustrated by the follow-
ing data.
Sera were measured together with controls during two
weeks. For the control serum a pooled serum was pre-
pared and aliquots were stored at -20°C. Two systems
of performance were used. One involved the standards
in duplicate only in the first rack and sera and control
in the following racks. The other system involved the
placement of sera and controls as described in Materials
and Methods.
The former system gave for the control a mean value of
226 nmol/1 with a standard deviation of 48 nmol/1
(n = 24); the latter system gave 220 nmol/1 but with a
standard deviation of 25 nmol (n = 22). This discrepancy
clearly illustrates that the procedure recommended should
be followed.
Falk et al. (10) report that the standard curve is stable
for 12 hours, but they use dihydrofolic acid reductase
from a different source, i.e. an enzyme preparation
from Lactobacillus casei which is not available to us. We
assume that the interfering factor is related to the source
of the enzyme preparation. If so, the method may be
modified to a procedure using only one set of standards
if other sources of enzyme preparations become available1).
An indication of the quality of the assay can be found in
the results when two different dilutions of the sample
are measured. Table 2 shows samples assayed either
undiluted or in different dilutions (dilutions were
performed with pipettes of the capilettor type Labora,
Mannheim Germany). The data show that there is a
direct relationship between methotrexate measured and
dilution used, provided the methotrexate concentrations
of the samples (diluted or undiluted) are not lower than
about 100 nmol/1 (see samples 2, 6, 7,16, 18, 19). Thus
samples with high methotrexate levels should not be so
diluted for measurement as to reduce their methotrexate
concentration below about 100 nmol/1. Table 3 shows
the interassay coefficients of variation for different
ranges. They were calculated from duplicates of assays
in routine samples performed during a period of two
months. The table shows that the present method permits
the assay of methotrexate with reasonable accuracy; an
accuracy which exceeds that of radioimmunoassay pro-
cedures for comparable ranges (see I.e. (5)). The value of
the decrease of absorbance per minute is changed by
0.05 as the concentration of methotrexate increases from
zero to 300 nmol/1. This compares favourably with the
method of Falk et al. (10), who describes a ΔΑ of approx.
0.015 under identical conditions of light path, temper-
ature and concentration range of methotrexate.
*) After completion of the manuscript, a paper (R. J. Brooks,
Clin. Chem. 24,518 (1978)) came to our attention which
describes the necessity of performing the assay on standards,
controls and sera within 30 minutes when dihydrofolate
reductase from bovine liver is used, while the standard curve
is more stable when the enzyme from Lactobacillus casei is
applied.
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Tab. 2. Results of measurement of methotrexate in all un-
diluted and diluted sera during an arbitrarily chosen period of 6
weeks.
Dilutions were done with normal serum. Except for samples 6,










































































































































































































The instability of some working reagents makes it
necessary to store them in a more stable stock form.
Consequently some time-consuming manipulations are
necessary at the start of the assay to prepare the final
working reagent solutions. This limits the speed of the
assay. On the other hand, application of the reaction
rate analyser significantly reduces the total time re-
quired for the assay.
In addition, the rate analyser enables the technician to
decide during the recording, whether the methotrexate
concentration of the sample is suitable for the range of
the standard curve. With the present method immediate
repeat of the assay at alternative dilutions is possible
until a measurable concentration of the diluted sample
is obtained. Within two hours, the result can be reported
to the clinician. If the laboratory is notified about 30
minutes in advance that a sample will be sent for
methotrexate assay, the time required for the analysis,
even if more samples are to be analysed at the same
time, is only 90 minutes because some reagents can be
prepared in the interval after notification. The need for
methotrexate analysis, it should be added, is as at rule
known much earlier than half an hour in advance.
This is of particular interest if adjustment of therapy is
urgent. This advantage is not offered by any of the other
methods such as microbiological (14), radioimmunological
(5-8) or direct ligand-binding assays (2-4). On the other
hand, the radioimmunological and direct ligand-binding
assays allow the measurement of very low concen-
trations of methotrexate (below 100 nmol/1), but this
is more of scientific than of clinical significance (15,16),
Examples of disappearance of methotrexate from serum
or cerebrospinal fluid as measured by the present
method are given iri figure 2. As can be expected
0.1 192
Fig. 2. Serum (circles) and cerebrospinal fluid (triangles) dis^
appearance curves. Time zero marks the end of a six
hour period of infusion (cirqles) or injection (triangles)
in an Ommaya reservoir. Patient Ά received 2 g/m?
methotrexate, patient Β 6 g/m*, patient C 10 mg and
patient D 3 mg.
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from the disappearance rate in serum, no toxicity
was observed in patient A. This is in complete
accordance with the data of Tattersall et al (15). In
patient B a slower disappearance was seen (serum
value after 48 hours: 770 nmol/1). After 72 hours
there was a transient rise, as described by Wang
et al (11). Severamyelosuppression followed as a
toxic effect. Patient C suffering from breast cancer
developed meningitis carcinomatosa. A delayed
elimination of methotrexate from the cerebrospinal
fluid was ascribed to disturbed cerebrospinal fluid
circulation around the cerebral convexities resulting
from carcinomatous adhesions. This was concluded
from the observation that methotrexate concen-
tration in cerebrospinal fluid obtained by lumbar
puncture was extremely low, while that in the ventricles
was high.
In another similar case (patient D), with an apparently
more normal cerebrospinal fluid circulation, the dis-
appearance of methotrexate was much faster. More
data obtained with the present method, involving a
study of the disappearance rate of methotrexate after
various routes of administration, will be given in another
report.
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